Anti GPRC5D x BCMA x CD3 trispecific antibody - Integral Molecular
Latest Information Update: 15 Jun 2024
At a glance
- Originator Integral Molecular
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Nov 2023 Anti GPRC5D x BCMA x CD3 trispecific antibody - Integral Molecular is available for licensing as of 14 Nov 2023. https://www.integralmolecular.com/
- 03 Nov 2023 Preclinical trials in Multiple myeloma in USA (Parenteral)